125 related articles for article (PubMed ID: 35005121)
1. The role of distinct co-mutation patterns with
Wang S; Jiang M; Yang Z; Huang X; Li N
Genes Dis; 2022 Jan; 9(1):245-251. PubMed ID: 35005121
[No Abstract] [Full Text] [Related]
2. Clinical outcomes and immune phenotypes associated with
Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
[TBL] [Abstract][Full Text] [Related]
3. The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.
Liu L; Li F; Zhao J; Zhuo X; Lai J; Wang J; Jiang F; Xu W; Luan F; Lin X; Yang S; Fu G
J Cancer; 2023; 14(6):952-965. PubMed ID: 37151388
[No Abstract] [Full Text] [Related]
4. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
Choi DH; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Lee SH
Transl Lung Cancer Res; 2023 Dec; 12(12):2448-2459. PubMed ID: 38205202
[TBL] [Abstract][Full Text] [Related]
5. Impact of
Bange E; Marmarelis ME; Hwang WT; Yang YX; Thompson JC; Rosenbaum J; Bauml JM; Ciunci C; Alley EW; Cohen RB; Langer CJ; Carpenter E; Aggarwal C
JCO Precis Oncol; 2019; 3():. PubMed ID: 31428721
[TBL] [Abstract][Full Text] [Related]
6. KRAS
Frost N; Kollmeier J; Vollbrecht C; Grah C; Matthes B; Pultermann D; von Laffert M; Lüders H; Olive E; Raspe M; Mairinger T; Ochsenreither S; Blum T; Hummel M; Suttorp N; Witzenrath M; Grohé C
Transl Lung Cancer Res; 2021 Feb; 10(2):737-752. PubMed ID: 33718018
[TBL] [Abstract][Full Text] [Related]
7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
8. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
9. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.
Roeper J; Falk M; Chalaris-Rißmann A; Lueers AC; Ramdani H; Wedeken K; Stropiep U; Diehl L; Tiemann M; Heukamp LC; Otto-Sobotka F; Griesinger F
Oncotarget; 2020 Jan; 11(3):250-264. PubMed ID: 32076486
[TBL] [Abstract][Full Text] [Related]
10. Primary Resistance to Immune Checkpoint Blockade in an
Kwack WG; Shin SY; Lee SH
Onco Targets Ther; 2020; 13():8901-8905. PubMed ID: 32982282
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
13.
Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
[No Abstract] [Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Correlation of
Albitar M; Sudarsanam S; Ma W; Jiang S; Chen W; Funari V; Blocker F; Agersborg S
Oncotarget; 2018 Mar; 9(17):13682-13693. PubMed ID: 29568386
[TBL] [Abstract][Full Text] [Related]
16. Breaking the 'Undruggable' Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with
Chmielewska I; Krawczyk P; Grenda A; Wójcik-Superczyńska M; Krzyżanowska N; Gil M; Milanowski J
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509393
[No Abstract] [Full Text] [Related]
17. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
18. The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.
Bai B; An X; Qu Q; Liu X; Liu Y; Wei L
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38872053
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a
An J; Yan M; Yu N; Chennamadhavuni A; Furqan M; Mott SL; Loeffler BT; Kruser T; Sita TL; Feldman L; Nguyen R; Pasquinelli M; Hanna NH; Abu Hejleh T
Transl Lung Cancer Res; 2021 Aug; 10(8):3608-3615. PubMed ID: 34584860
[TBL] [Abstract][Full Text] [Related]
20. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
[Next] [New Search]